Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 540

1.

[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].

Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P.

Ideggyogy Sz. 2013 May 30;66(5-6):165-74. Review. Hungarian.

PMID:
23909016
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
4.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
5.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
6.

Novel oral anticoagulants in non-valvular atrial fibrillation.

Potpara TS, Lip GY.

Best Pract Res Clin Haematol. 2013 Jun;26(2):115-29. doi: 10.1016/j.beha.2013.07.008. Epub 2013 Jul 21. Review.

PMID:
23953900
7.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
8.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

9.

Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.

Lenchus JD.

Hosp Pract (1995). 2013 Feb;41(1):49-60. doi: 10.3810/hp.2013.02.1007.

PMID:
23466967
10.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
11.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
12.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
13.

Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.

Salazar CA, del Aguila D, Cordova EG.

Cochrane Database Syst Rev. 2014 Mar 27;(3):CD009893. doi: 10.1002/14651858.CD009893.pub2. Review.

PMID:
24677203
14.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
15.

Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.

Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.

Thromb Haemost. 2013 Feb;109(2):328-36. doi: 10.1160/TH12-08-0539. Epub 2012 Nov 22.

PMID:
23179181
16.

Stroke prevention in atrial fibrillation: do we still need warfarin?

Diener HC, Weber R, Lip GY, Hohnloser SH.

Curr Opin Neurol. 2012 Feb;25(1):27-35. doi: 10.1097/WCO.0b013e32834e604a. Review.

PMID:
22143201
17.

[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].

Calvo Romero JM.

Rev Clin Esp. 2011 Mar;211(3):142-6. doi: 10.1016/j.rce.2010.12.001. Epub 2011 Mar 2. Spanish.

PMID:
21371701
18.

Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.

Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K, Ackermann D, Clemens A, Bartels DB.

Am Heart J. 2014 Mar;167(3):329-34. doi: 10.1016/j.ahj.2013.12.006. Epub 2013 Dec 19.

PMID:
24576516
19.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
20.

[Prevention of cardioembolic stroke].

Gil Núñez A.

Neurologia. 2012 Mar;27 Suppl 1:15-26. doi: 10.1016/S0213-4853(12)70004-X. Review. Spanish.

Supplemental Content

Support Center